MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
MYC oncogene is a transcription factor with a wide array of functions affecting cellular
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …
activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
Protein phosphatase 2A: a target for anticancer therapy
D Perrotti, P Neviani - The lancet oncology, 2013 - thelancet.com
Summary Protein phosphatase 2A (PP2A), one of the main serine–threonine phosphatases
in mammalian cells, maintains cell homoeostasis by counteracting most of the kinase-driven …
in mammalian cells, maintains cell homoeostasis by counteracting most of the kinase-driven …
Pushing the limits of targeted therapy in chronic myeloid leukaemia
T O'hare, MS Zabriskie, AM Eiring… - Nature Reviews …, 2012 - nature.com
Tyrosine kinase inhibitor (TKI) therapy targeting the BCR-ABL1 kinase is effective against
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
chronic myeloid leukaemia (CML), but is not curative for most patients. Minimal residual …
How I treat CML blast crisis
R Hehlmann - Blood, The Journal of the American Society of …, 2012 - ashpublications.org
Blast crisis (BC) remains the major challenge in the management of chronic myeloid
leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR …
leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR …
Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A
K Pavic, N Gupta, JD Omella, R Derua, A Aakula… - Nature …, 2023 - nature.com
The protein phosphatase 2A (PP2A) heterotrimer PP2A-B56α is a human tumour
suppressor. However, the molecular mechanisms inhibiting PP2A-B56α in cancer are poorly …
suppressor. However, the molecular mechanisms inhibiting PP2A-B56α in cancer are poorly …
Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target
A Khanna, JE Pimanda, J Westermarck - Cancer research, 2013 - AACR
Abstract Protein phosphatase 2A (PP2A) complexes function as tumor suppressors by
inhibiting the activity of several critical oncogenic signaling pathways. Consequently …
inhibiting the activity of several critical oncogenic signaling pathways. Consequently …
[HTML][HTML] The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance
PP Ruvolo - BBA clinical, 2016 - Elsevier
Aberrant activation of signal transduction pathways can transform a normal cell to a
malignant one and can impart survival properties that render cancer cells resistant to …
malignant one and can impart survival properties that render cancer cells resistant to …
Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update
Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
gene, which encodes a constitutive active tyrosine kinase considered to be the pathogenic …
Management of chronic myeloid leukemia in advanced phase
M Bonifacio, F Stagno, L Scaffidi, M Krampera… - Frontiers in …, 2019 - frontiersin.org
Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …